Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility Study of Neoadjuvant Gemcitabine/Nab-Paclitaxel and HIGRT in Pancreatic Cancer
NCT02318095Completed
- Sponsor
- Duke University
- Start
- Feb 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic cancer (PC), sponsored by Duke University. Primary endpoint: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen at 6 months. Started Feb 2015; status: completed.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02318095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318095.